Combining AFM13, a bispecific CD30/CD16 antibody, with cytokine-activated cord blood-derived NK cells facilitates CAR-like responses against CD30+ malignancies
Kerbauy et al.
Clinical Cancer Research; 27: 3744-3756.
Kerbauy et al.
Clinical Cancer Research; 27: 3744-3756.
Pahl et al.
AACR 2021 - AFM24
Sawas et al.
ASH 2020 - AFM13
Bartlett et al.
Blood 2020; 136: 2401–2409.
Reusch et al.
AACR 2020 - AFM24
Harstrick et al.
ASCO 2020 - AFM13
Ellwanger et al.
NK2019 - ROCK®
Marin et al.
NK2019 - AFM13
Ellwanger et al.
mAbs 2019; 11:899-918.
Sawas et al.
15-ICML - AFM13